Vicore Pharma is focused on unlocking the potential of a new class of drugs known as Angiotensin II type 2 receptor agonists (ATRAGs), with a strong emphasis on treating idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH)
Vicore Pharma is focused on unlocking the potential of a new class of drugs known as Angiotensin II type 2 receptor agonists (ATRAGs), with a strong emphasis on treating idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).